CA
NZ
UK
AU
IND
US
Biotech and health technology rarely move as one. On any given week theNasdaqComposite houses companies chasing a first product approval alongside others fighting to stay listed. Arrowhead Pharmaceuticals (NASDAQ:ARWR), Whitehawk Therapeutics (NASDAQ:WHWK), Cullinan Therapeutics (NASDAQ:CGEM), DarioHealth (NASDAQ:DRIO) and Maravai LifeSciences (NASDAQ:MRVI) illustrate that spread.
Grouping biotech and health-technology stocks together can flatten some very real differences. In this list, one company is still spending to prove a drug works, another is banking hundreds of millions in quarterly product sales, and a third barely fits the biotech label at …
Healthcare investors spent the first half of 2026 watching biotech shake off a long malaise. As September opens, five Nasdaq-listed names capture the sector's range: Viatris (NASDAQ:VTRS), a global generics and specialty pharma heavyweight; Alkermes (NASDAQ:ALKS), a neuroscience developer with a closely watched orexin …
Biotech spent much of the early 2020s as the market's problem child. In September 2026 the mood is noticeably different. A run of clinical readouts, a friendlier funding backdrop and renewed dealmaking appetite have pulledCapitalback toward the risk end of healthcare, and theNasdaqComposite, where …
Walk down the biotech aisle of theNasdaqComposite in September 2026 and you find no single mood. One company is booking hundreds of millions in new drug sales; another is nursing under $10 million in cash. One just watched a flagship depression program collapse; another …
Biotech used to trade as a single mood. In September 2026 it does not. The companies grouped under theNasdaqComposite's health-technology umbrella now range from pre-revenue science projects burning cash toward a first readout to profitable commercial machines raising full-year guidance. Sana Biotechnology (NASDAQ:SANA), Delcath …
Health technology rarely moves as one block. On any given week theNasdaqComposite carries a profitable imaging giant, a clinical-stage obesity play burning cash toward a distant readout, and a small-cap chasing its first product revenue, all filed under the same sector label. GE HealthCare …
Biotech remains one of the most idiosyncratic corners of theNasdaqComposite. These companies rarely move on macro data; they move on regulatory letters, trial readouts and cash runways. Achieve Life Sciences (NASDAQ:ACHV), Revolution Medicines (NASDAQ:RVMD), MBX Biosciences (NASDAQ:MBX), Prelude Therapeutics (NASDAQ:PRLD) and AN2 Therapeutics (NASDAQ:ANTX) …
Group APYX, AXSM, STOK, CRBP and COCH together and you get a fair cross-section of what healthcare means inside theNasdaqComposite this September. One is a small aesthetics-device maker fighting for operating leverage. One is a fast-scaling central-nervous-system drug company already selling three products. One …
TheNasdaqComposite is still shorthand for megacap technology, but tucked inside it is a cluster of healthcare-services companies whose fortunes turn on very different levers: clinician supply,Medicareand Medicaid rates, payer contracts and the slow grind toward operating profitability. Aveanna Healthcare (NASDAQ:AVAH), Starling Oncology (NASDAQ:STLN), NeoGenomics …
Please wait processing your request...